Inspiremd Inc (NSPR) Stock Price, Quote & News

Company Profile

InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases in Europe, Latin America, the Middle East, and the Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard neuroprotection system for transcarotid access and neuro protection, as w...

Industry: Medical Devices

Sector: Healthcare

Phone: 888 776 6804

Website: www.inspiremd.com

Address:

6303 Waterford District Drive, Suite 215, Miami, United States

Shadowsdontlie Jan. 30 at 8:23 PM

$NSPR

0 · Reply

trek10 Jan. 29 at 9:58 PM

$NSPR Neutral bias prevailing

0 · Reply

Threeways Jan. 28 at 5:51 PM

$NSPR looking at the brighter side. The first quarter of US sales was $500K more than any of their other markets by far. If they can double each quarter (if not slightly more than double) they should be profitable by EOY. Lets hope for 1 million in US sales from Q4

1 · Reply

OfficialStocktwitsUser Jan. 25 at 3:40 AM

$NSPR RSI: 33.33, MACD: -0.0876 Vol: 0.15, MA20: 1.75, MA50: 1.86 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

zigsfrd Jan. 23 at 10:42 PM

$NSPR Are these men of science avoiding a sexual harassment suit?😂😂😂

0 · Reply

Threeways Jan. 22 at 6:17 PM

$NSPR i’ve been wondering. Why would they accelerate kathryn Arnolds equity awards for resigning? Seems wild to me unless she was pushed out.

2 · Reply

woodstockery Jan. 21 at 3:49 PM

$NSPR nvm

0 · Reply

woodstockery Jan. 21 at 3:02 PM

$NSPR do my eyes deceive me?

0 · Reply

Jerry000 Jan. 20 at 7:26 PM

$NSPR It's been awhile since I have posted. This is the trial that I have been involved in on the Gguard stent.https://clinicaltrials.gov/study/NCT06653387?term=CGuard%20Prime%20Carotid%20Stent%20System&rank=1c I was the third person in the Cincinnati area at TriHealth by Dr. Muck to have this procedure in February 2025 I just wanted to give an update after talking with the doctor and the research company that everything has been excellent and the research company told me that they have excellent reviews on this particular study. My annual visit with the research company and the doctor is in the 1st of February of 2026 which will conclude the research on me. I am not trying to hype anything other than to give an update. With a little research on the link that I provided, they have three different studies going on. Maybe their will be good news soon

2 · Reply

DocRosen Jan. 20 at 6:06 PM

$NSPR good to see some volume today

1 · Reply

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 12, 2026, 9:00 AM EST - 19 days ago

InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)

Nov 24, 2025, 7:30 AM EST - 2 months ago

Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting

Nov 19, 2025, 4:42 PM EST - 2 months ago

InspireMD to Participate in Upcoming Piper Sandler 37th Annual Healthcare Conference

Nov 4, 2025, 1:06 PM EST - 3 months ago

InspireMD, Inc. (NSPR) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 7:00 AM EST - 3 months ago

InspireMD Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 7:30 AM EST - 3 months ago

InspireMD Names Peter A. Soukas, M.D.

Oct 21, 2025, 4:05 PM EDT - 3 months ago

InspireMD to Announce Third Quarter 2025 Financial Results

Sep 17, 2025, 8:00 AM EDT - 4 months ago

InspireMD Announces the Appointment of Dan Dearen to its Board of Directors

Aug 27, 2025, 9:00 AM EDT - 5 months ago

InspireMD to Present at Upcoming H.C. Wainwright 27th Annual Global Investment Conference

Aug 5, 2025, 12:30 PM EDT - 6 months ago

InspireMD, Inc. (NSPR) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 8:00 AM EDT - 6 months ago

InspireMD Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 8:31 AM EDT - 6 months ago

InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors

Jul 31, 2025, 8:30 AM EDT - 6 months ago

InspireMD Announces Combined Financings of $58 Million

Jul 22, 2025, 7:00 AM EDT - 6 months ago

InspireMD to Announce Second Quarter 2025 Financial Results

Jul 9, 2025, 7:00 AM EDT - 7 months ago

InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke

Jun 24, 2025, 4:05 PM EDT - 7 months ago

InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke

Jun 13, 2025, 9:00 AM EDT - 8 months ago

InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke

Jun 3, 2025, 4:05 PM EDT - 8 months ago

InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer

May 9, 2025, 12:07 PM EDT - 9 months ago

InspireMD, Inc. (NSPR) Q1 2025 Earnings Call Transcript

May 9, 2025, 7:00 AM EDT - 9 months ago

InspireMD Reports First Quarter 2025 Financial Results

Apr 30, 2025, 9:00 AM EDT - 9 months ago

InspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference

Apr 25, 2025, 9:00 AM EDT - 10 months ago

InspireMD to Announce First Quarter 2025 Financial Results

Mar 26, 2025, 9:00 AM EDT - 11 months ago

InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference

Mar 12, 2025, 1:53 PM EDT - 11 months ago

InspireMD, Inc. (NSPR) Q4 2024 Earnings Call Transcript

Mar 12, 2025, 7:00 AM EDT - 11 months ago

InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 8:00 AM EST - 1 year ago

InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results

Feb 13, 2025, 7:00 AM EST - 1 year ago

InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures

Dec 9, 2024, 7:00 AM EST - 1 year ago

InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)

Nov 25, 2024, 4:05 PM EST - 1 year ago

InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

Nov 12, 2024, 10:20 AM EST - 1 year ago

InspireMD, Inc. (NSPR) Q3 2024 Earnings Call Transcript

Oct 15, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System

Oct 7, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System

Sep 16, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

Aug 9, 2024, 8:58 AM EDT - 1 year ago

InspireMD, Inc. (NSPR) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 8:09 AM EDT - 1 year ago

InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 5, 2024, 7:00 AM EDT - 1 year ago

InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment

Jul 30, 2024, 7:00 AM EDT - 1 year ago

InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th

May 28, 2024, 8:53 AM EDT - 1 year ago

InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024

May 14, 2024, 10:50 AM EDT - 1 year ago

InspireMD Inc. (NSPR) Q1 2024 Earnings Call Transcript

May 14, 2024, 7:00 AM EDT - 1 year ago

InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024, 7:00 AM EDT - 1 year ago

InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th

Apr 3, 2024, 8:59 AM EDT - 1 year ago

InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024, 7:00 AM EDT - 2 years ago

InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

Mar 6, 2024, 11:30 AM EST - 2 years ago

InspireMD Inc. (NSPR) Q4 2023 Earnings Call Transcript

Mar 6, 2024, 7:00 AM EST - 2 years ago

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Feb 28, 2024, 7:00 AM EST - 2 years ago

InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th

Feb 12, 2024, 7:00 AM EST - 2 years ago

InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System

Jan 31, 2024, 7:00 AM EST - 2 years ago

InspireMD Receives CE Mark Recertification Under EU's New Medical Device Regulation (MDR) Regulatory Framework

Jan 3, 2024, 7:00 AM EST - 2 years ago

InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America

Shadowsdontlie Jan. 30 at 8:23 PM

$NSPR

0 · Reply

trek10 Jan. 29 at 9:58 PM

$NSPR Neutral bias prevailing

0 · Reply

Threeways Jan. 28 at 5:51 PM

1 · Reply

OfficialStocktwitsUser Jan. 25 at 3:40 AM

0 · Reply

zigsfrd Jan. 23 at 10:42 PM

$NSPR Are these men of science avoiding a sexual harassment suit?😂😂😂

0 · Reply

Threeways Jan. 22 at 6:17 PM

$NSPR i’ve been wondering. Why would they accelerate kathryn Arnolds equity awards for resigning? Seems wild to me unless she was pushed out.

2 · Reply

woodstockery Jan. 21 at 3:49 PM

$NSPR nvm

0 · Reply

woodstockery Jan. 21 at 3:02 PM

$NSPR do my eyes deceive me?

0 · Reply

Jerry000 Jan. 20 at 7:26 PM

2 · Reply

DocRosen Jan. 20 at 6:06 PM

$NSPR good to see some volume today

1 · Reply

Threeways Jan. 19 at 9:01 PM

$NSPR updated investor presentation states over 70,000 stents sold to date up 5,000 stents from last presentation. Will sales be a nice surprise or just slightly better; ready to see

0 · Reply

TrkDvr Jan. 16 at 6:19 PM

$NSPR Hey, I own a bunch of this stock. So here's what's good about it. Big cash balance with a D/E of 5.26%. Biggest problem seems to be very weak sales & a EBITDA of $-46.49M. I think a practical sales program to offset this current operating loss would definitely excite the market. We don't need a quarterly report to update shareholders on unit sales. This can be done monthly. Make it happen!

1 · Reply

LoyalShark Jan. 16 at 3:42 PM

$NSPR Talking with an exec at a firm that follows NSPR. Aske him when they would be buying NSPR -- his reply was they were giving Slosman all the time he needs to create a better price for a buy out. They are betting on him to do what he has proven he does best --- destroy shareholder value.

1 · Reply

LoyalShark Jan. 16 at 3:40 PM

$NSPR No words for how pathetic Slossman has been creating value. $1.63 / share A diasater of magnificant proportions. So infuriatingly sad.

0 · Reply

Jonnie5 Jan. 16 at 2:06 PM

$NSPR

0 · Reply

LoyalShark Jan. 16 at 3:51 AM

$NSPR

0 · Reply

LoyalShark Jan. 16 at 3:49 AM

$NSPR Its time we gather the troops a dispell of Slossman. BIggest Piece of Shit CEO I have ever EVER encountered. I am going to make it my life goal to get this MF out of our company.

0 · Reply

woodstockery Jan. 15 at 12:12 AM

$NSPR weird seeing green tbh. Let's hit $5 already. Anyone need a stent? I know a guy....

0 · Reply

zigsfrd Jan. 14 at 9:45 PM

$NSPR Nice positive pr from the JPM. We will see.

2 · Reply

arcuy Jan. 14 at 8:20 PM

$NSPR Trust the process

1 · Reply

RedDogSailor Jan. 14 at 3:28 PM

$NSPR This is really happening? An And not a word from management?

3 · Reply

arcuy Jan. 14 at 4:37 AM

$NSPR if this is not going up tomorrow, is going down then

1 · Reply

Market Cap	68.64M
Revenue (ttm)	7.01M
Net Income (ttm)	-32.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-456.63%
Debt to Equity Ratio	0.00

Volume	12,300
Avg Vol	60,914
Day's Range	N/A - N/A
Shares Out	42.37M
Stochastic %K	24%
Beta	0.72
Analysts	Strong Sell
Price Target	$4.50